|
Dr. Rob Scott brings nearly two decades of pharmaceutical research and development experience to AtheroGenics, particularly in the areas of cardiovascular and metabolic medicine. From August 2002 until May 2006, Dr. Scott served as Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer. Prior to joining AtheroGenics, Dr. Scott spent 10 years with the Pfizer Pharmaceutical Group, where he was most recently vice president and worldwide medical therapeutic head of the Cardiovascular and Metabolic Group. In this role, he was responsible for the global development of products including Lipitor, Norvasc, Tikosyn, Accupril, the Dual Therapy Compound (combination of Norvasc and Lipitor), Glucotrol XL and Exubera (inhaled insulin). During his tenure at Pfizer, Dr. Scott also acted as medical director of Pfizer's Cardiovascular Risk Factors Group in the U.S., as well as medical director of Pfizer Laboratories South Africa. Before joining Pfizer, Dr. Scott served as medical adviser for Janssen Pharmaceutica, where he ran the clinical trials department at the company's South African affiliate.
Scott studied medicine at the University of Cape Town, South Africa, and practiced in the Cape Town area for more than six years before beginning his career in pharmaceutical development. | 